ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Files An 8-K Financial Statements and Exhibits
Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

ACELRX PHARMACEUTICALS INC Exhibit
EX-99.1 2 ex_117265.htm EXHIBIT 99.1 ex_117265.htm Exhibit 99.1           AcelRx receives European Commission approval for DZUVEOTM   AcelRx’s DZUVEO receives EU approval for management of acute moderate to severe pain in medically monitored settings   REDWOOD CITY,…
To view the full exhibit click here

About ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.